Company profile PGEN

Precigen Inc
precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies.... in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua Show More
Quarter analysis & expected interest

There is not enough data for Precigen gene therapy to provide analysis

Correlation between past revenue and Precigen gene therapy search interest

There is not enough data for Precigen gene therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen gene therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen gene and cellular therapies to provide analysis

Correlation between past revenue and Precigen gene and cellular therapies search interest

There is not enough data for Precigen gene and cellular therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen gene and cellular therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen biotechnology to provide analysis

Correlation between past revenue and Precigen biotechnology search interest

There is not enough data for Precigen biotechnology to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen biotechnology to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen UltraVector platform to provide analysis

Correlation between past revenue and Precigen UltraVector platform search interest

There is not enough data for Precigen UltraVector platform to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen UltraVector platform to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen mbIL15 gene to provide analysis

Correlation between past revenue and Precigen mbIL15 gene search interest

There is not enough data for Precigen mbIL15 gene to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen mbIL15 gene to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen rheoswitch therapeutic system to provide analysis

Correlation between past revenue and Precigen rheoswitch therapeutic system search interest

There is not enough data for Precigen rheoswitch therapeutic system to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen rheoswitch therapeutic system to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen kill switches to provide analysis

Correlation between past revenue and Precigen kill switches search interest

There is not enough data for Precigen kill switches to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen kill switches to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen ActoBiotics platform to provide analysis

Correlation between past revenue and Precigen ActoBiotics platform search interest

There is not enough data for Precigen ActoBiotics platform to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen ActoBiotics platform to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen corporate governance to provide analysis

Correlation between past revenue and Precigen corporate governance search interest

There is not enough data for Precigen corporate governance to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen corporate governance to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen ISS governance qualityscore to provide analysis

Correlation between past revenue and Precigen ISS governance qualityscore search interest

There is not enough data for Precigen ISS governance qualityscore to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen ISS governance qualityscore to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for PGEN
Earnings date: 2024-02-29 After close
Company name: Precigen Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T14:15:42Z

Analyst Upgrades
Citizens Maintains Market Outperform on Precigen, Raises Price Target to $11

2026-05-14T10:38:11Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $11

2026-05-13T16:05:00-04:00

PR Newswire
Precigen Reports First Quarter 2026 Financial Results and Business Updates

2026-05-07T16:05:00-04:00

PR Newswire
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

2026-04-07T11:00:00Z

AccessWire
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

2026-03-30T08:30:00-04:00

PR Newswire
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

2026-03-26T16:08:58Z

Analyst Upgrades
These Analysts Boost Their Forecasts On Precigen Following Q4 Results

2026-03-26T13:07:27Z

Analyst Upgrades
Citizens Maintains Market Outperform on Precigen, Raises Price Target to $9

2026-03-26T12:41:35Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $10

2026-03-25T16:05:00-04:00

PR Newswire
Precigen Reports Full Year 2025 Financial Results and Business Updates

2026-03-11T16:05:00-04:00

PR Newswire
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

2026-01-20T08:05:00-05:00

PR Newswire
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

2026-01-12T08:00:00-05:00

PR Newswire
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-05T16:05:00-05:00

PR Newswire
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-11-14T13:00:34Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $9